Payment overview · 2025
General Payments
$412.23
20 reported records · 14 companies
Healthcare provider profile · identity verified
Shaun E Laurie, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TALLAHASSEE, FL · NPI 1952344285
Verified facts
What the public records show
CMS Open Payments records show Shaun E Laurie, M.D. received $412.23 in general payments during 2025 across 20 reported records.
Abbott Laboratories accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1394 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1394 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.08 | 14.6% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $47.89 | 11.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.61 | 9.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.43 | 9.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.52 | 7.9% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $28.06 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.41 | 6.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.17 | 5.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.73 | 5.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.67 | 5.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.83 | 5.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.82 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.32 | 3.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.69 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.23 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1394 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
153 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1394 | 144 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
409 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1394 | 144 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1871 | 317 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1657 | 301 |
| Eliquis | Apixaban | 1394 | 144 |
| Gabapentin | Gabapentin | 1260 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1141 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1106 | 201 |
| Furosemide | Furosemide | 1056 | 177 |
| Potassium Chloride | Potassium Chloride | 938 | 157 |
| Trazodone Hcl | Trazodone Hcl | 893 | 138 |
| Levetiracetam | Levetiracetam | 868 | 107 |
| Januvia | Sitagliptin Phosphate | 793 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 706 | 142 |
| Carvedilol | Carvedilol | 694 | 108 |
| Losartan Potassium | Losartan Potassium | 684 | 115 |
| Metformin Hcl | Metformin Hcl | 660 | 114 |
| Metoprolol Tartrate | Metoprolol Tartrate | 645 | 105 |
| Lisinopril | Lisinopril | 588 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 523 | 105 |
| Donepezil Hcl | Donepezil Hcl | 490 | 78 |
| Sertraline Hcl | Sertraline Hcl | 473 | 67 |
| Divalproex Sodium | Divalproex Sodium | 470 | 69 |
| Mirtazapine | Mirtazapine | 445 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 439 | 81 |
| Simvastatin | Simvastatin | 414 | 56 |
| Jardiance | Empagliflozin | 409 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 390 | 96 |
| Allopurinol | Allopurinol | 380 | 60 |
| Valsartan | Valsartan | 377 | 79 |
| Omeprazole | Omeprazole | 368 | 72 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 306 | 40 |
| Famotidine | Famotidine | 284 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 269 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 54 |
| Latanoprost | Latanoprost | 255 | 52 |
| Tradjenta | Linagliptin | 249 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 53 |
| Memantine Hcl | Memantine Hcl | 245 | 35 |
| Nifedipine Er | Nifedipine | 241 | 38 |
| Lamotrigine | Lamotrigine | 232 | 24 |
| Megestrol Acetate | Megestrol Acetate | 230 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 225 | 46 |
| Doxazosin Mesylate | Doxazosin Mesylate | 224 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 221 | 34 |
| Entresto | Sacubitril/Valsartan | 219 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 207 | 69 |
| Clonidine Hcl | Clonidine Hcl | 195 | 53 |
| Finasteride | Finasteride | 190 | 35 |
| Lactulose | Lactulose | 183 | 56 |
| Tramadol Hcl | Tramadol Hcl | 177 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 51 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 173 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 169 | 35 |
| Azithromycin | Azithromycin | 167 | 116 |
| Myrbetriq | Mirabegron | 153 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 153 | 77 |
| Xarelto | Rivaroxaban | 150 | 18 |
| Meloxicam | Meloxicam | 148 | 25 |
| Ezetimibe | Ezetimibe | 138 | 24 |
| Scopolamine | Scopolamine | 138 | 12 |
| Montelukast Sodium | Montelukast Sodium | 137 | 25 |
| Spironolactone | Spironolactone | 132 | 26 |
| Ibuprofen | Ibuprofen | 131 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 128 | 94 |
| Novolog Flexpen | Insulin Aspart | 126 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 123 | 22 |
| Baclofen | Baclofen | 121 | 37 |
| Brimonidine Tartrate | Brimonidine Tartrate | 118 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 34 |
| Levofloxacin | Levofloxacin | 113 | 86 |
| Prednisone | Prednisone | 112 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 38 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 109 | 26 |
| Labetalol Hcl | Labetalol Hcl | 108 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 21 |
| Alendronate Sodium | Alendronate Sodium | 107 | 18 |
| Olanzapine | Olanzapine | 107 | 15 |
| Metformin Hcl Er | Metformin Hcl | 102 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 101 | 21 |
| Aptiom | Eslicarbazepine Acetate | 101 | suppressed |
| Aripiprazole | Aripiprazole | 101 | 15 |
| Farxiga | Dapagliflozin Propanediol | 101 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 99 | 11 |
| Etodolac | Etodolac | 99 | 22 |
| Oxcarbazepine | Oxcarbazepine | 98 | 17 |
| Alprazolam | Alprazolam | 97 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 97 | 27 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 97 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 96 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 94 | 16 |
| Nystatin | Nystatin | 94 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 88 | 13 |
| Warfarin Sodium | Warfarin Sodium | 87 | suppressed |
| Mounjaro | Tirzepatide | 85 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 85 | 22 |
| Ramipril | Ramipril | 84 | 14 |
| Risperidone | Risperidone | 83 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 13 |
| Dorzolamide Hcl | Dorzolamide Hcl | 79 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 15 |
| Pregabalin | Pregabalin | 78 | 25 |
| Atenolol | Atenolol | 76 | suppressed |
| Lorazepam | Lorazepam | 76 | 26 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 75 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 56 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | suppressed |
| Dutasteride | Dutasteride | 71 | 13 |
| Irbesartan | Irbesartan | 71 | 20 |
| Linzess | Linaclotide | 71 | 14 |
| Bupropion Xl | Bupropion Hcl | 70 | suppressed |
| Glimepiride | Glimepiride | 68 | 19 |
| Primidone | Primidone | 68 | suppressed |
| Colchicine | Colchicine | 67 | 17 |
| Topiramate | Topiramate | 67 | 13 |
| Brilinta | Ticagrelor | 66 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 66 | suppressed |
| Celecoxib | Celecoxib | 64 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 20 |
| Lithium Carbonate | Lithium Carbonate | 64 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 17 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 63 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 63 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 62 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 11 |
| Amoxicillin | Amoxicillin | 61 | 49 |
| Ceftriaxone | Ceftriaxone Sodium | 60 | 41 |
| Midodrine Hcl | Midodrine Hcl | 59 | suppressed |
| Ketoconazole | Ketoconazole | 58 | 32 |
| Temazepam | Temazepam | 58 | 12 |
| Fluconazole | Fluconazole | 57 | 37 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 57 | suppressed |
| Ozempic | Semaglutide | 57 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 17 |
| Lacosamide | Lacosamide | 56 | 11 |
| Haloperidol | Haloperidol | 55 | suppressed |
| Torsemide | Torsemide | 55 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 54 | 21 |
| Timolol Maleate | Timolol Maleate | 54 | 13 |
| Clonazepam | Clonazepam | 53 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 18 |
| Methocarbamol | Methocarbamol | 52 | 28 |
| Sucralfate | Sucralfate | 52 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 48 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 48 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 47 | 39 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | suppressed |
| Bumetanide | Bumetanide | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 11 |
| Glipizide | Glipizide | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 15 |
| Methimazole | Methimazole | 42 | suppressed |
| Rybelsus | Semaglutide | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 27 |
| Clonidine | Clonidine | 39 | suppressed |
| Metronidazole | Metronidazole | 39 | 24 |
| Santyl | Collagenase Clostridium Hist. | 39 | 23 |
| Movantik | Naloxegol Oxalate | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Alogliptin | Alogliptin Benzoate | 36 | suppressed |
| Budesonide | Budesonide | 36 | 15 |
| Desloratadine | Desloratadine | 36 | 15 |
| Ofloxacin | Ofloxacin | 36 | 13 |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Rhopressa | Netarsudil Mesylate | 36 | suppressed |
| Rivastigmine | Rivastigmine | 36 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Phenytoin | Phenytoin | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Indapamide | Indapamide | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 24 |
| Risedronate Sodium | Risedronate Sodium | 31 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | 12 |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Enulose | Lactulose | 29 | 12 |
| Haloperidol Lactate | Haloperidol Lactate | 29 | 15 |
| Lidocaine Hcl | Lidocaine Hcl | 29 | 27 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 23 | 19 |
| Glucagon Emergency Kit | Glucagon | 23 | 13 |
| Hydroxyurea | Hydroxyurea | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 11 |
| Erythromycin | Erythromycin Base | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 22 | suppressed |
| Neomycin Sulfate | Neomycin Sulfate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Procrit | Epoetin Alfa | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Verquvo | Vericiguat | 21 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Fycompa | Perampanel | 20 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Cimetidine | Cimetidine | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 19 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Linezolid | Linezolid | 17 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Fanapt | Iloperidone | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Xcopri | Cenobamate | 14 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.23 · 20 records | Abbott Laboratories | ABRYSVO, AIRSUPRA, APLIGRAF, CAPLYTA, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, INCEPTIV, Nayzilam, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VOQUEZNA, Veozah, Wegovy, ZENPEP, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error